<DOC>
	<DOCNO>NCT02490085</DOCNO>
	<brief_summary>The introduction insulin pump therapy patient type 2 diabetes use multiple daily injection poorly control consider order improve glycemic control . Recent development continuous glucose sensor insulin infusion pump motivate research toward `` closed-loop '' strategy regulate glucose level patient diabetes . In closed-loop strategy , pump ( ) infusion rate alter base computer generate recommendation rely continuous glucose sensor reading . This study confirm feasibility potential closed-loop strategy improve glycemic control reduce risk hypoglycemia patient type 2 diabetes target population likely benefit strategy.The objective ot study compare efficacy closed-loop strategy multiple daily injection regulate glucose level 24 hour elderly adult type 2 diabetes intensive insulin therapy . The investigator hypothesize closed-loop strategy increase time spent target range adult type 2 diabetes compare multiple daily injection .</brief_summary>
	<brief_title>Closed-loop Control Glucose Levels ( Artificial Pancreas ) 24 Hours Adults With Type 2 Diabetes Under Intensive Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Type 2 diabetes . 2 . Males females â‰¥ 55 year old . 3 . Body mass index 25 kg/m2 4 . Non fragile define base Moorhouse et al . scale [ 23 ] . 5 . Using least 3 insulin injection per day . However , basal insulin injection must inject bedtime without injection basal insulin morning . Combination antidiabetic therapy acceptable long therapy introduce least 6 week prior 1 intervention keep stable along protocol . 6 . HbA1c 7.5 % . 1 . Advanced 1 . Nephropathy define creatinine clearance &lt; 30 ml/min . 2 . Retinopathy proliferative retinopathy recent ( &lt; 3 month ) eye bleed laser therapy . If patient undergone panphotocoagulation inclusion acceptable . 3 . Autonomic neuropathy clinically significant gastroparesis accord investigator evaluation . 2 . Recent ( &lt; 6 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . 3 . A recent ( &lt; 2 month ) injury body limb , muscular disorder , use medication significant medical disorder injury , medication disease judgment investigator affect ability walk . 4 . A recent ( &lt; 2 month ) infection need IV antibiotic hospitalization 5 . Severe hypoglycemic episode within two week screen . 6 . Current use glucocorticoid medication ( route administration except low dose stable inhale ) . 7 . Recent initiation dose modification ( &lt; 2 month ) therapy know interfere glucose metabolism ( e.g . neuroleptic , antipsychotic , etc . ) 8 . Known suspect allergy trial product meal content . 9 . Other serious medical illness likely interfere study participation ability complete trial judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Closed-loop strategy</keyword>
	<keyword>Artificial pancreas</keyword>
	<keyword>Insulin</keyword>
	<keyword>Elderly</keyword>
	<keyword>Multiple daily injection</keyword>
	<keyword>Hypoglycemia</keyword>
</DOC>